866-997-4948(US-Canada Toll Free)

Cancer Genetics Inc (CGIX) - Product Pipeline Analysis, 2016 Update

Published By :

GlobalData

Published Date : Dec 2016

Category :

Cancer

No. of Pages : 40 Pages

Summary

Cancer Genetics Inc (CGI) is a pharmaceutical company that provides diagnostics products and services in oncology areas. The company offers products such as CGH Microarrays, Next-Generation Sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic information to healthcare professionals, biopharma companies, and cancer centers. CGIs clinical services include expand DX, test menu, complete program, and summation report. The company offers a range of pharmacogenomics testing services for clinical oncologists, cancer centers, and research institutions, and for biotech and biopharma customers engaged in clinical trials. It works in research collaboration with cancer centers to develop and validate proprietary tests. CGI is headquartered in Rutherford, New Jersey, the US.

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Cancer Genetics Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Cancer Genetics Inc Company Overview 6
Cancer Genetics Inc Company Snapshot 6
Cancer Genetics Inc Pipeline Products and Clinical Trials Overview 7
Cancer Genetics Inc Pipeline Analysis Overview 10
Key Facts 10
Cancer Genetics Inc - Major Products and Services 11
Cancer Genetics Inc Pipeline Products by Development Stage 12
Cancer Genetics Inc Pipeline Products Overview 14
Diagnostic Panel - Myelodysplastic Syndrome 14
Diagnostic Panel - Myelodysplastic Syndrome Product Overview 14
FHACT Test - Head and Neck Cancer 15
FHACT Test - Head and Neck Cancer Product Overview 15
FReCaD Renal Cancer Test 16
FReCaD Renal Cancer Test Product Overview 16
LeukA - Leukemia 17
LeukA - Leukemia Product Overview 17
MatBA Diagnostic Test - Marginal Zone Lymphoma 18
MatBA Diagnostic Test - Marginal Zone Lymphoma Product Overview 18
MatBA Diagnostic Test - Multiple Myeloma 19
MatBA Diagnostic Test - Multiple Myeloma Product Overview 19
Next-Gen DNA Sequencing Assay - Follicular Lymphoma 20
Next-Gen DNA Sequencing Assay - Follicular Lymphoma Product Overview 20
Next-Generation Sequencing Based Test - Lung Cancer 21
Next-Generation Sequencing Based Test - Lung Cancer Product Overview 21
UGenRA - Cervix 22
UGenRA - Cervix Product Overview 22
UGenRA - Endometrium 23
UGenRA - Endometrium Product Overview 23
UGenRA - Ovarian Cancer 24
UGenRA - Ovarian Cancer Product Overview 24
UroGenRA - Bladder 25
UroGenRA - Bladder Product Overview 25
UroGenRA - Prostate 26
UroGenRA - Prostate Product Overview 26
Cancer Genetics Inc - Key Competitors 27
Cancer Genetics Inc - Key Employees 28
Cancer Genetics Inc - Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 31
Cancer Genetics Inc, Recent Developments 31
Dec 01, 2016: Cancer Genetics and Leading Collaborators to Present Innovative Insights That Will Advance Precision Medicine in Diffuse Large B-cell Lymphoma (DLBCL) at American Society of Hematology (ASH) Annual Meeting 2016 31
Nov 10, 2016: Cancer Genetics Announces Strong Third Quarter with 68% Year over Year Revenue Growth and Highlights Path to Future Profitability 31
Nov 10, 2016: Sirona Dx Expands Next Generation Sequencing Services to Include Oncomine Focus Assay for Pharmaceutical Clients 33
Nov 02, 2016: Cancer Genetics Launches Focus::Renal, a Unique, Comprehensive and Highly Sensitive Next Generation Sequencing (NGS) Panel for Enabling Precision and Personalized Medicine in Renal Cancers 33
Aug 17, 2016: Cancer Genetics Strengthens Position as a Leader in Myeloid Cancer Diagnosis and Management Receiving New York State Approval for Focus::Myeloid, a Targeted NGS Panel for Improved Diagnosis, Risk Stratification, and Therapy Selection of Patients with 34
Aug 09, 2016: Cancer Genetics Reports Second Quarter 2016 Financial Results and Provides Company Updates 34
Jun 30, 2016: Cancer Genetics, Inc. Receives New York State Approval for Focus::CLL, a Unique NGS Panel for Chronic Lymphocytic Leukemia, Reinforcing CGIs Market-Leading Position in the Diagnosis and Management of B-Cell Cancers 36
Jun 27, 2016: Cancer Genetics Names Healthcare Technology Industry Veteran John Jay Roberts as COO and Executive Vice President of Finance 36
Jun 02, 2016: Cancer Genetics Partners with ArcherDX to Offer Archer NGS Assays as a Sequencing Service for Biotech and Pharma 37
May 17, 2016: Cancer Genetics Launches The Most Comprehensive & Clinically Actionable Next Generation Sequencing Panel in Precision Medicine, FOCUS::Lymphoma 37
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
Cancer Genetics Inc Pipeline Products and Clinical Trials Overview 7
Cancer Genetics Inc Pipeline Products by Equipment Type 7
Cancer Genetics Inc Pipeline Products by Indication 9
Cancer Genetics Inc, Key Facts 10
Cancer Genetics Inc, Major Products and Services 11
Cancer Genetics Inc Number of Pipeline Products by Development Stage 12
Cancer Genetics Inc Pipeline Products Summary by Development Stage 13
Diagnostic Panel - Myelodysplastic Syndrome - Product Status 14
Diagnostic Panel - Myelodysplastic Syndrome - Product Description 14
FHACT Test - Head and Neck Cancer - Product Status 15
FHACT Test - Head and Neck Cancer - Product Description 15
FReCaD Renal Cancer Test - Product Status 16
FReCaD Renal Cancer Test - Product Description 16
LeukA - Leukemia - Product Status 17
LeukA - Leukemia - Product Description 17
MatBA Diagnostic Test - Marginal Zone Lymphoma - Product Status 18
MatBA Diagnostic Test - Marginal Zone Lymphoma - Product Description 18
MatBA Diagnostic Test - Multiple Myeloma - Product Status 19
MatBA Diagnostic Test - Multiple Myeloma - Product Description 19
Next-Gen DNA Sequencing Assay - Follicular Lymphoma - Product Status 20
Next-Gen DNA Sequencing Assay - Follicular Lymphoma - Product Description 20
Next-Generation Sequencing Based Test - Lung Cancer - Product Status 21
Next-Generation Sequencing Based Test - Lung Cancer - Product Description 21
UGenRA - Cervix - Product Status 22
UGenRA - Cervix - Product Description 22
UGenRA - Endometrium - Product Status 23
UGenRA - Endometrium - Product Description 23
UGenRA - Ovarian Cancer - Product Status 24
UGenRA - Ovarian Cancer - Product Description 24
UroGenRA - Bladder - Product Status 25
UroGenRA - Bladder - Product Description 25
UroGenRA - Prostate - Product Status 26
UroGenRA - Prostate - Product Description 26
Cancer Genetics Inc, Key Employees 28
Table 7: Cancer Genetics Inc, Other Locations 29
Cancer Genetics Inc, Subsidiaries 29

List of Figures
Cancer Genetics Inc Pipeline Products by Equipment Type 8
Cancer Genetics Inc Pipeline Products by Development Stage 12

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *